BTIG Research Reiterates “Buy” Rating for Ascentage Pharma Group International (NASDAQ:AAPG)

Ascentage Pharma Group International (NASDAQ:AAPG)‘s stock had its “buy” rating reiterated by analysts at BTIG Research in a research note issued to investors on Thursday,Benzinga reports. They presently have a $48.00 price objective on the stock. BTIG Research’s price target would indicate a potential upside of 98.18% from the stock’s current price.

Other equities research analysts also recently issued research reports about the company. Rodman & Renshaw assumed coverage on Ascentage Pharma Group International in a report on Tuesday, January 13th. They set a “buy” rating and a $48.00 target price for the company. Lucid Cap Mkts upgraded shares of Ascentage Pharma Group International to a “strong-buy” rating in a research note on Monday, December 15th. Oppenheimer started coverage on shares of Ascentage Pharma Group International in a research report on Thursday, December 4th. They set an “outperform” rating and a $45.00 target price on the stock. Finally, Truist Financial set a $51.00 price target on Ascentage Pharma Group International in a research note on Monday, November 24th. One analyst has rated the stock with a Strong Buy rating and six have assigned a Buy rating to the company’s stock. According to MarketBeat.com, Ascentage Pharma Group International has a consensus rating of “Buy” and an average price target of $48.00.

Ascentage Pharma Group International Trading Down 1.1%

Ascentage Pharma Group International stock opened at $24.22 on Thursday. The stock’s 50 day moving average is $25.13 and its 200-day moving average is $31.36. The company has a quick ratio of 1.53, a current ratio of 1.54 and a debt-to-equity ratio of 1.31. Ascentage Pharma Group International has a 12 month low of $17.56 and a 12 month high of $48.45.

Hedge Funds Weigh In On Ascentage Pharma Group International

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Tema Etfs LLC bought a new stake in shares of Ascentage Pharma Group International during the 2nd quarter worth approximately $610,000. XY Capital Ltd boosted its holdings in shares of Ascentage Pharma Group International by 224.2% in the 3rd quarter. XY Capital Ltd now owns 18,120 shares of the company’s stock valued at $707,000 after purchasing an additional 12,530 shares in the last quarter. UBS Group AG increased its stake in shares of Ascentage Pharma Group International by 149.4% in the 3rd quarter. UBS Group AG now owns 18,345 shares of the company’s stock valued at $716,000 after purchasing an additional 10,988 shares during the last quarter. Hsbc Holdings PLC acquired a new position in shares of Ascentage Pharma Group International during the 2nd quarter worth $391,000. Finally, Citadel Advisors LLC bought a new stake in shares of Ascentage Pharma Group International during the 3rd quarter worth $383,000.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.